Twice-Yearly Sunlenca Works Well for Initial HIV Treatment
From Poz Magazine online… Sunlenca (lenacapavir), a long-acting injectable medication recently approved for treatment-experienced people with multidrug-resistant HIV, also works well for people starting antiretroviral therapy for the first time. Results from the CALIBRATE trial showed that around 90% of study participants who used Sunlenca—either as daily pills or injections every six months—in combination with […]
Living with HIV and limited mobility
From POZ online… […] An analysis of national 2017 data found that 45% of people living with HIV report some form of disability—and that mobility disabilities were the most common. Fully one in four people reported them. And that’s among all adults living with HIV. At middle age, men with HIV walked more slowly, and […]
Combination Anti-HIV Antibody Infusions Suppress Virus for Sustained Period
From HIV.gov… Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a small study published today in the journal Nature . The findings suggest that combination bNAb therapy might offer a […]
Researchers document third known case of HIV remission
From HIV.gov… A woman with HIV who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months despite cessation of antiretroviral therapy (ART), according to a presentation at today’s Conference on Retroviruses and Opportunistic Infections (CROI). This is the third known case of […]
Today is National Black HIV/AIDS Awareness Day
From POZ Magazine online… Monday, February 7, marks National Black HIV/AIDS Awareness Day (NBHAAD) 2022. By numerous measures, Black Americans are disproportionately affected by the HIV epidemic. NBHAAD highlights related challenges while raising awareness about prevention, testing, treatment and more. “This #NBHAAD we are focused on equity,” tweeted the Centers for Disease Control and Prevention’s […]
Two People With HIV Suppressed Virus After Stopping Treatment
From US News and World Report… In one patient, viral suppression lasted nearly three and a half years, with occasional rebounds in virus counts. The other patient had nearly complete HIV suppression for close to four years, but then had a big surge when he was infected with a different HIV strain, a situation called […]
New National Challenge to Reduce HIV-Related Stigma and Disparities
From POZ.com… The U.S. Department of Health and Human Services (HHS) has launched The HIV Challenge, a national competition to engage communities to reduce HIV-related stigma and increase prevention and treatment among racial and ethnic minority people. The HIV Challenge is part of a new partnership between the Office of the Assistant Secretary for Health […]
Ten-year Italian study shows that people with HIV remain undetectable for 97% of the time
From aidsmap.com… Long-term monitoring of people with HIV with an undetectable viral load has shown that viral suppression is rarely lost, enforcing the validity of ‘U=U’ (Undetectable equals Untransmittable) messaging, according to Italian research published in the online edition of AIDS. The study involved over 8000 HIV-positive individuals taking antiretroviral therapy (ART) and with viral suppression […]
FDA approves the first and only complete long-acting regimen for HIV treatment
A press release from ViiV Healthcare: ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva […]
U.S. Waits on Approval of Long-Acting HIV Treatment as European Union Gives the Green Light
From the TheBodyPro… The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon. On Dec. 21, the European Commission authorized use of the long-acting injectable HIV treatment regimen of cabotegravir and rilpivirine (LA-CAB+RPV) for combination […]